Biogen Inc. (BIIB) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Biogen reported revenue of $9.89B, up 2.2% from $9.68B the year before. Net income was $1.29B (a 13.1% net margin), or $8.79 per diluted share. Gross margin was 75.7% and operating margin was 51.1%. Operating activities generated $2.20B of cash, leaving $2.05B of free cash flow. At fiscal year end, Biogen held $29.44B in total assets against $11.18B in total liabilities.
Open the full interactive Biogen financials → Quarterly statements, key ratios, valuation history and price charts.
Biogen Key Stats
| Share Price | $228.90 |
|---|---|
| Market Cap | $34.04B |
| P/E Ratio | 26.0 |
| Revenue YoY Growth | +2.2% |
| 52-Week Range | $142.26 – $229.41 |
| Shares Outstanding | 147.7 million (basic, 2026 Q2) |
Biogen Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $13.44B | $10.98B | $10.17B | $9.84B | $9.68B | $9.89B |
| Cost of Goods Sold | $1.81B | $2.11B | $2.28B | $2.53B | $2.31B | $2.40B |
| Gross Profit | $11.64B | $8.87B | $7.90B | $7.30B | $7.37B | $7.49B |
| Operating Income | $4.55B | $2.84B | $5.49B | $4.75B | $4.96B | $5.05B |
| Pre-Tax Income | $5.05B | $1.75B | $3.59B | $1.30B | $1.91B | $1.56B |
| Income Tax | $992.3M | $52.5M | $632.8M | $135.3M | $273.8M | $263.6M |
| Net Income | $4.00B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B |
| Diluted EPS | $24.80 | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
Biogen Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.53B | $2.28B | $2.48B | $2.74B |
| Net Income | $466.5M | -$48.9M | $319.5M | $97.5M |
| Diluted EPS | $3.17 | -$0.33 | $2.15 | $0.66 |
Biogen Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Current Assets | $6.89B | $7.86B | $9.79B | $6.86B | $7.46B | $8.97B |
| Total Assets | $24.62B | $23.88B | $24.55B | $26.84B | $28.05B | $29.44B |
| Current Liabilities | $3.74B | $4.30B | $3.27B | $3.43B | $5.53B | $3.35B |
| Total Long-Term Debt | $7.43B | $6.27B | $6.28B | $6.94B | $6.30B | $6.29B |
| Total Liabilities | $13.93B | $12.92B | $11.17B | $12.05B | $11.33B | $11.18B |
| Shareholders' Equity | $10.70B | $10.90B | $13.40B | $14.80B | $16.72B | $18.26B |
Biogen Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $4.23B | $3.64B | $1.38B | $1.55B | $2.88B | $2.20B |
| Cash From Investing | -$608.6M | -$563.7M | $1.58B | -$4.10B | -$799.2M | -$1.37B |
| Cash From Financing | -$5.27B | -$2.09B | -$1.75B | $149.3M | -$683.5M | -$301.9M |
| Free Cash Flow | $3.81B | $3.38B | $1.14B | $1.27B | $2.72B | $2.05B |
Figures from Biogen's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biogen financials page for every line item.
Biogen Company Profile
| Ticker | BIIB |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000875045 |
Frequently Asked Questions
What was Biogen's revenue in fiscal 2025?
Biogen (BIIB) reported revenue of $9.89B for fiscal 2025.
What is Biogen's annual revenue history?
Biogen's annual revenue by fiscal year: 2020: $13.44B; 2021: $10.98B; 2022: $10.17B; 2023: $9.84B; 2024: $9.68B; 2025: $9.89B.
What was Biogen's net income in fiscal 2025?
Biogen reported net income of $1.29B for fiscal 2025.
What was Biogen's earnings per share (EPS) in fiscal 2025?
Biogen's diluted EPS was $8.79 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Biogen generate in fiscal 2025?
Biogen generated $2.05B of free cash flow in fiscal 2025.
What was Biogen's revenue last quarter?
In its most recent reported quarter (2026 Q2), Biogen reported revenue of $2.74B.
How much debt does Biogen have?
Biogen reported $6.29B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Biogen are outstanding?
Biogen reported a weighted average of 147.7 million basic shares outstanding in 2026 Q2.
What is Biogen's market cap?
Based on its latest closing price, Biogen (BIIB) has a market capitalization of about $34.04B.
When does Biogen's fiscal year end?
Biogen's fiscal year end, as registered with the SEC, is December 31.
Where is Biogen headquartered?
Biogen lists its business address in Cambridge, Massachusetts in its SEC filings.
Biogen Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →